Cutaneous Melanoma Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0040978 (Cutaneous Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs